Aethlon Medical(US:AEMD) Globenewswire·2026-03-06 13:35Core Insights - Aethlon Medical, Inc. will present at the Life Sciences Investor Forum on March 12, 2026, with CEO and CFO Jim Frakes leading the presentation [1][2]. Company Overview - Aethlon Medical, Inc. is a clinical-stage medical device company based in San Diego, California, focused on developing the Hemopurifier to address unmet needs in oncology and infectious diseases [7]. - The Hemopurifier is designed to remove enveloped viruses and tumor-derived extracellular vesicles (EVs) from circulation, utilizing a unique platform that combines plasma separation, size exclusion, and affinity binding [5]. Product Highlights - The Hemopurifier has received U.S. Food and Drug Breakthrough Device Designation for treating advanced or metastatic cancer unresponsive to standard therapies and for addressing life-threatening viruses without approved therapies [6]. - The device has shown efficacy in both in vitro studies and human subjects, indicating its potential in cancer treatment and infectious diseases [5]. Recent Developments - Clinical Progress: The second cohort of the Australian oncology trial is actively progressing, demonstrating continued clinical execution [8]. - Scientific Advancement: Ongoing research on extracellular vesicles (EVs) includes data on Long COVID, supporting the Hemopurifier's potential as a multi-indication therapeutic approach [8]. - Technology Development: Evaluation of Hemopurifier compatibility with simplified blood treatment systems is ongoing to broaden clinical applications [8]. - Operational Efficiency: The company has maintained disciplined cost controls, resulting in lower year-to-date operating expenses compared to the previous year [8].